15 articles · Updated · The Wall Street Journal · Apr 24
Over 710,000 Americans received TAVR between 2015 and 2024, with nearly one-third of valve replacements in patients aged 40 to 65 now using TAVR despite limited long-term data.
Premature valve deterioration in younger, more active patients is driving a steep rise in complex explant surgeries, which are riskier than initial procedures and challenging for both patients and surgeons.
Doctors and device makers are studying long-term outcomes and developing improved valves, while guidelines still recommend surgery for most under-65 patients; TAVR remains vital for high-risk or elderly individuals.
As follow-up surgery gets safer, is the long-term danger of a TAVR valve now overstated?
With TAVR failures rising, should doctors reverse course on this popular heart procedure?
Conflicting studies show TAVR is both safer and riskier than surgery. Who should patients believe?
The TAVR market is booming. Is patient safety taking a backseat to billion-dollar profits?
Will next-gen polymer valves solve TAVR's durability crisis, or is it a false promise?
Premature TAVR Valve Failure in Younger Patients: Causes, Risks, and High-Mortality Explantation Outcomes
Overview
The expansion of TAVR to younger patients under 65 has led to a rise in premature valve failures, driven by unique patient factors, longer life expectancy, and procedural challenges. Younger patients often outlive their first valve, making structural valve deterioration inevitable. Non-structural issues like leaks and infections also accelerate valve damage. Explantation surgery, though increasingly common, carries higher risks and is more complex, especially with self-expanding valves. While redo-TAVR offers a less invasive option, anatomical constraints and durability concerns limit its use in younger patients. High-volume centers and multidisciplinary teams improve outcomes, highlighting the need for lifetime management strategies and more durable valve technologies.